A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Doxercalciferol

Vitamin D2 Analog class · 9 generic manufacturers · 13 ANDAs filed at FDA.

First FDA approval2019-09-26
Generic availableYes · 9 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$902,583 in CY2024 Part D spend2K claims · 580 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
93 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Doxercalciferol used for?

Doxercalciferol is a Vitamin D2 Analog medication tracked in Medicare Part D.

Is there a generic for Doxercalciferol?

Yes. 13 ANDAs filed at FDA, 9 generic manufacturers currently shipping.

How much does my plan pay for Doxercalciferol?

NADAC pricing data not currently available for this drug.

Is Doxercalciferol on the FDA shortage list?

Doxercalciferol has been discontinued by its manufacturer(s).

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Vitamin D2 Analog1 alternative in D1
01
Paricalcitol
Brand: Zemplar
$1.06Lowest NADAC
10Generic mfrs
$4.5MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.